Dynavax Technologies Corporation (DVAX) : During the past 4 weeks, traders have been relatively bearish on Dynavax Technologies Corporation (DVAX), hence the stock is down -34.7% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -33.28% relative to the S&P 500. The 4-week change in the price of the stock is -34.79% and the stock has fallen -32.94% in the past 1 week.
The stock has recorded a 20-day Moving Average of 32.18% and the 50-Day Moving Average is 29.2%.The 200 Day SMA reached 42.87%. Dynavax Technologies Corporation has dropped 35.1% during the last 3-month period . Year-to-Date the stock performance stands at -54.84%.
Dynavax Technologies Corporation (NASDAQ:DVAX): The stock opened in the green at $16.01 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $16.19 and a low of $10.14 for the day. The stock did not find buyers even at the lows and closed at $10.91 recording a loss of -31.56%. 15,822,144 shares exchanged hands during the trading day. The stock had closed at $15.94 in the previous days trading.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.